Breast Surgery Practice Questions

Q: An elderly female presented with 'Peau de orange appearance' of the breast. What is it likely to be associated with?

Obstruction of cutaneous lymphatics. **Explanation:** **Peau d’orange** (French for "orange peel skin") is a classic clinical sign of advanced breast malignancy, specifically inflammatory breast cancer. **1. Why the Correct Answer is Right:** The appearance is caused by the **obstruction of cutaneous lymphatics** by tumor emboli. When the superficial lymphatic drainage is blocked, it leads to localized lymphedema of the skin. However, the skin remains tethered to the underlying subcutaneous tissue by the **suspensory ligaments of Cooper**. As the skin swells (edema), these tethered points create characteristic "pits" or dimples, resembling the texture of an orange peel. **2. Why the Incorrect Options are Wrong:** * **A. Drug reaction:** While drug reactions can cause skin rashes or generalized edema (angioedema), they do not typically cause the localized, pitted "orange peel" texture associated with lymphatic obstruction. * **C. Postoperative scarring:** Scarring usually results in skin retraction or puckering due to fibrosis, but it lacks the diffuse edematous, pitted appearance of peau d'orange. * **D. Tumor necrosis:** Necrosis within a tumor may lead to skin ulceration or discharge, but it does not directly cause the specific lymphatic-mediated edema seen in this condition. **3. Clinical Pearls for NEET-PG:** * **Significance:** Peau d’orange is a hallmark of **Inflammatory Breast Cancer** (T4d in TNM staging). * **Differential Diagnosis:** It can also be seen in severe cases of mastitis or breast abscess, though the clinical context (fever, pain) usually differs. * **Histology:** If a skin biopsy is performed, it often shows **lymphatic invasion** by malignant cells in the dermal lymphatics. * **Staging:** The presence of peau d'orange automatically classifies the breast cancer as **Stage T4**, regardless of the size of the underlying tumor.

Q: A mobile, variegated large lump in the breast of a 20-year-old female is most likely due to what condition?

Cystosarcoma phylloides. **Explanation:** The correct answer is **Cystosarcoma phylloides** (Phyllodes tumor). **Why it is correct:** Phyllodes tumors are fibroepithelial neoplasms that typically present as **large, painless, mobile, and rapidly growing** breast masses. The term "variegated" refers to the heterogeneous consistency (areas of cystic degeneration, hemorrhage, and solid fleshy parts) often felt on palpation or seen on imaging/gross section. While they can occur at any age, they frequently present in younger women (though the peak incidence is slightly older than fibroadenomas). Their hallmark is the rapid increase in size, often stretching the overlying skin and appearing "bosselated." **Why the other options are incorrect:** * **Medullary Carcinoma:** Though it can be well-circumscribed and mimic a benign lesion, it is a rare subtype of invasive ductal carcinoma and typically does not reach the massive, variegated proportions seen in Phyllodes at a young age. * **Inflammatory Carcinoma:** This is a highly aggressive clinical diagnosis characterized by the "peau d'orange" appearance, warmth, and redness due to dermal lymphatic invasion. It presents as a diffuse swelling rather than a mobile, variegated lump. * **Lobular Carcinoma:** This usually presents as an ill-defined thickening rather than a discrete, mobile lump and is more common in older, postmenopausal women. **NEET-PG High-Yield Pearls:** * **Leaf-like pattern:** On histology, Phyllodes tumors show a characteristic "leaf-like" stromal overgrowth. * **Treatment:** Wide local excision with a **1 cm margin** is the gold standard. Lymph node dissection is not routinely required as these tumors spread hematogenously (like sarcomas). * **Fibroadenoma vs. Phyllodes:** If a "fibroadenoma" suddenly starts growing rapidly in a young patient, always suspect a Phyllodes tumor. * **Grading:** They can be benign, borderline, or malignant based on stromal cellularity and mitotic index.

Q: Which of the following is NOT a poor prognostic marker in breast cancer?

ER positivity. ### Explanation In breast cancer management, prognostic markers help predict the natural history of the disease (recurrence and survival), while predictive markers help determine the likely response to specific therapies. **Why ER Positivity is the Correct Answer:** **Estrogen Receptor (ER) positivity** is generally considered a **favorable prognostic factor**. Tumors that are ER-positive tend to be well-differentiated (lower grade), have a lower proliferation rate, and are less aggressive compared to ER-negative tumors. Furthermore, ER positivity is a strong **predictive marker** for a good response to endocrine therapies like Tamoxifen or Aromatase Inhibitors, leading to improved overall survival. **Analysis of Incorrect Options (Poor Prognostic Markers):** * **PCNA (Proliferating Cell Nuclear Antigen) Positivity:** This is a marker of cell proliferation. High levels indicate rapid tumor growth and high mitotic activity, which correlates with a poorer prognosis. * **Her-2/neu Positivity:** Overexpression of this tyrosine kinase receptor (found in ~15-20% of cases) is associated with aggressive tumor behavior, increased risk of recurrence, and resistance to conventional endocrine therapy. * **p53 Overexpression:** Mutations in the *TP53* tumor suppressor gene lead to the accumulation of stable p53 protein. This is associated with high-grade tumors, increased genomic instability, and a worse clinical outcome. **Clinical Pearls for NEET-PG:** * **Most Important Prognostic Factor:** Number of **axillary lymph nodes** involved. * **Most Important Predictive Factor:** ER/PR status (for hormonal therapy) and Her-2/neu status (for Trastuzumab). * **Triple Negative Breast Cancer (TNBC):** Lacks ER, PR, and Her-2/neu; it carries the worst prognosis among molecular subtypes. * **Cathepsin D & Ki-67:** High levels of these markers also indicate a poor prognosis.

Q: Which type of breast cancer has the worst prognosis?

Inflammatory breast carcinoma. **Explanation:** The prognosis of breast cancer is determined by its clinical presentation, histological subtype, and molecular markers. **Inflammatory Breast Carcinoma (IBC)** is clinically the most aggressive form of breast cancer. It is characterized by the rapid onset of erythema, edema (peau d'orange), and warmth. The underlying pathophysiology involves the **blockage of dermal lymphatics by tumor emboli**, which leads to rapid systemic dissemination. By definition, IBC is classified as at least **Stage T4d**, meaning it is locally advanced at the time of diagnosis, leading to the worst overall survival rates among the options provided. **Analysis of Incorrect Options:** * **Mucinous (Colloid) Carcinoma:** This is a rare subtype seen typically in elderly women. It is characterized by slow growth and has a **favorable prognosis** compared to invasive ductal carcinoma (NOS). * **Medullary Carcinoma:** Despite having high-grade cytological features and being frequently associated with BRCA1 mutations, it carries a **better prognosis** than typical invasive ductal carcinoma due to a robust host immune response (lymphocytic infiltrate). * **Triple Negative Breast Carcinoma (TNBC):** While TNBC has a poor prognosis due to the lack of targeted therapies (ER, PR, and HER2 negative) and high recurrence rates, **Inflammatory Breast Cancer is clinically more lethal** and aggressive in its immediate progression. **Clinical Pearls for NEET-PG:** * **Peau d'orange:** Caused by cutaneous lymphatic edema; the skin is tethered by sweat glands, creating a dimpled appearance. * **Diagnosis:** IBC is a **clinical diagnosis**; however, a punch biopsy of the skin showing dermal lymphatic invasion is a classic pathological finding. * **Treatment:** The standard of care is Neoadjuvant Chemotherapy followed by Modified Radical Mastectomy and Radiotherapy.

Q: Which of the following is not a benign condition of the breast?

Paget's disease of the nipple. **Explanation:** The correct answer is **Paget’s disease of the nipple** because it is a form of **intraepidermal adenocarcinoma**. It is not a benign condition; rather, it is a clinical manifestation of an underlying breast malignancy. In approximately 95% of cases, Paget’s disease is associated with either an underlying **Ductal Carcinoma In Situ (DCIS)** or an invasive carcinoma. Clinically, it presents as a chronic, eczematous-like lesion of the nipple-areola complex that does not respond to topical steroids. **Analysis of Incorrect Options:** * **Fibroadenoma (A):** The most common benign breast tumor in young women ("Breast Mouse"). It arises from the terminal duct lobular unit and is characterized by a well-defined, mobile, non-tender mass. * **Cystosarcoma Phyllodes (B):** Despite the historical name "sarcoma," the majority of Phyllodes tumors (approx. 60–75%) are **benign**. While they have malignant potential, they are categorized as fibroepithelial lesions. * **Galactocele (D):** A benign milk-containing retention cyst that typically occurs in lactating women due to the blockage of a milk duct. **NEET-PG High-Yield Pearls:** * **Paget’s Disease Hallmark:** Presence of **Paget cells** (large cells with clear/pale cytoplasm and prominent nucleoli) in the epidermis. * **Clinical Tip:** Unlike simple eczema, Paget’s disease typically involves the **nipple first** and then spreads to the areola. * **Investigation of Choice:** A full-thickness **punch biopsy** of the nipple-areola complex is required for diagnosis, followed by mammography to locate the underlying malignancy.

Q: Which of the following statements regarding the Oncotype DX test is true?

It is a 21-gene assay. **Explanation:** The **Oncotype DX** is a genomic test used primarily in early-stage breast cancer to guide the decision regarding adjuvant chemotherapy. **1. Why Option B is correct:** Oncotype DX is a **21-gene expression assay** (16 cancer-related genes and 5 reference genes). It uses reverse-transcriptase polymerase chain reaction (RT-PCR) on paraffin-embedded tumor tissue to calculate a **Recurrence Score (RS)** ranging from 0 to 100. This score quantifies the risk of distant recurrence at 10 years. **2. Why the other options are incorrect:** * **Option A:** It is specifically indicated for **Hormone Receptor-positive (ER/PR+), HER2-negative** cancers. It is not used for triple-negative or HER2-positive cancers. * **Option C:** While it predicts the risk of recurrence, its primary clinical utility is predicting the **benefit of adjuvant chemotherapy**, not hormonal therapy (hormonal therapy is generally indicated for all ER+ patients). * **Option D:** Traditionally, it is used for **Lymph Node-negative** disease. While its use has expanded to some post-menopausal patients with 1–3 positive nodes (based on the RxPONDER trial), its classic and most high-yield indication for exams remains node-negative disease. **Clinical Pearls for NEET-PG:** * **TAILORx Trial:** This landmark study established that patients with an RS of 0–25 generally do not benefit from chemotherapy and can be treated with endocrine therapy alone. * **MammaPrint:** Another genomic test, but it is a **70-gene assay** (uses microarray). * **Indication Summary:** Early-stage, ER+, HER2-, Node-negative breast cancer.

Question 1

An elderly female presented with 'Peau de orange appearance' of the breast. What is it likely to be associated with?

Accepted Answer

Obstruction of cutaneous lymphatics

Answer

Drug reaction

Answer

Postoperative scarring

Answer

Tumor necrosis

Question 2

A 75-year-old hypertensive lady has a 2 x 2 cm infiltrating duct cell carcinoma in the subareolar region. There are no palpable lymph nodes and no distant metastases. However, she had been treated for pulmonary tuberculosis 20 years ago. What is the best course of management?

Accepted Answer

Modified radical mastectomy followed by hormone therapy

Answer

Modified radical mastectomy followed by radiotherapy

Answer

Modified radical mastectomy followed by 6 cycles of chemotherapy

Answer

Breast conservation surgery followed by radiotherapy

Question 3

A mobile, variegated large lump in the breast of a 20-year-old female is most likely due to what condition?

Accepted Answer

Cystosarcoma phylloides

Answer

Medullary carcinoma

Answer

Inflammatory carcinoma

Answer

Lobular carcinoma

Question 4

Which of the following is NOT a poor prognostic marker in breast cancer?

Accepted Answer

ER positivity

Answer

PCNA Positivity

Answer

Her 2 neu positivity

Answer

p53 over expression

Question 5

The proper treatment for lobular carcinoma in situ (LCIS) includes which of the following components?

Accepted Answer

Close follow-up.

Answer

Radiation after excision.

Answer

Mirror-image biopsy of the opposite breast.

Answer

Mastectomy and regional node dissection.

Question 6

Which type of breast cancer has the worst prognosis?

Accepted Answer

Inflammatory breast carcinoma

Answer

Mucinous carcinoma

Answer

Triple negative breast carcinoma

Answer

Medullary breast carcinoma

Question 7

Which of the following is not a benign condition of the breast?

Accepted Answer

Paget's disease of the nipple

Answer

Fibroadenoma

Answer

Cystosarcomaphyllodes

Answer

Galactocele

Question 8

Breast examination is done yearly in patients with which of the following conditions?

Accepted Answer

Family history of breast cancer

Answer

Multiple fibroadenoma

Answer

Carcinoma cervix

Answer

Endometrial carcinoma

Question 9

A 45-year-old premenopausal woman undergoes a left breast lumpectomy for a 1.5 cm, lymph node positive, hormone sensitive invasive breast cancer. She receives chemotherapy, radiotherapy, and is on tamoxifen. What is the recommended follow-up after therapy?

Accepted Answer

Routine clinical examination every 3-6 months for the first 5 years after treatment as well as continued yearly mammography.

Answer

Blood tumor markers drawn every 3-6 months after treatment.

Answer

Routine monitoring of liver function tests (LFTs) every 3-6 months after treatment.

Answer

Yearly bone scans.

Question 10

Which of the following statements regarding the Oncotype DX test is true?

Accepted Answer

It is a 21-gene assay

Answer

Used for hormone receptor-negative cancers

Answer

Predicts the benefit of adjuvant hormonal therapy

Answer

Used for lymph node-positive cancers

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?